

SUBJECT INDEX TO VOLUME 1

Ab-taxoid conjugates.....	132	Aspartic protease inhibitors.....	83
design of.....	132	in clinical development.....	85
2-3-/4-Acylaminocinnamyl- <i>N</i> -hydroxyamides.....	245	to target HIV protease.....	83
as novel synthetic HDAC inhibitors.....	245	to target plasmepsins.....	91
biological evaluation of.....	245	to target renin.....	88
chemistry of.....	247		
<i>in vitro</i>	253	Bcr-Abl.....	301
maize HD2/HD1-B/HD1-A enzyme inhibition of.....	253	Bioactive natural products.....	575
synthesis of.....	245	from <i>Arcyria cinerea</i>	584
Adenosine phosphonoacetic acid.....	529	from <i>Arcyria ferruginea</i>	579
effect of NDP kinase.....	529	from <i>Cribraria cencellata</i>	579
kinetic studies of NDP kinase in.....	531,532	from <i>Cribraria purpurea</i>	578
NDP kinase activity assays on.....	530	from <i>Didymium iridis</i>	575
Amine receptors.....	406	from <i>Fuligo candida</i>	586
γ -Aminobutyric acid B (GABA B).....	418	from <i>Lindblabia tubulina</i>	578
Aminopyrimidinimino isatin analogues.....	277	from <i>Lycogala epidendrum</i>	580
antimycobacterial screening of.....	284	from myxomycetes.....	575
biological investigation of.....	278	from <i>Physarum melleum</i>	576
chemistry of.....	277	from <i>Physarum rigidum</i>	576
design of.....	277	from <i>Tubifera casparyi</i>	580
experimental protocols for.....	279	from <i>Tubifera dimorphothea</i>	587
HIV-IRT assay of.....	284	isolation of.....	575
<i>in vitro</i> antibacterial activity of.....	284	metabolites of cultured myxomycetes as.....	575
<i>in vivo</i> antibacterial activity of.....	284		
synthesis of.....	277	Bruceantin.....	3
Antibody therapy.....	521	anticancer assays of.....	6
Anticancer agents.....	135	antimalarial assays of.....	5
novel fatty acid-second generation taxoid		antimicrobial assays of.....	7
conjugates as.....	135	as antimalarial agents.....	3
Anticoagulant aptamer.....	206	biological activity of.....	5
control of activity of.....	206	chemistry of.....	4
Anticonvulsant enamines.....	371	future perspectives of.....	8
assessments of.....	371	structure of.....	4
chemistry of.....	372	synthesis of A/B-ring partial analogs of.....	3
molecular modeling aspects of.....	371,374		
QSAR of.....	371	Bruceantin partial analog.....	4
Anticonvulsants.....	371	anticancer assays of.....	6
as sodium channel blocking agents.....	371	antimalarial assays of.....	5
chemistry of.....	372	antimicrobial assays of.....	7
pharmacophore model for.....	371	biological activity of.....	5
Anti-HIV screening.....	284	future perspectives of.....	8
in CEM cells.....	284	synthetic methodology to prepare.....	4
in MT-4 cells.....	284		
Apoptosis.....	49	Catalase.....	565
in bronchial asthma.....	52	measurement of.....	565
in pulmonary emphysema.....	53	CC-1065.....	13
in pulmonary fibrosis.....	51	novel achiral <i>seco</i> -amino-cyclopropylindoline	
Artemisinin.....	106	(CI) analog of.....	13
preparation of (+)-deoxoartemisinin from.....	106	CCK1 receptor antagonists.....	501
preparation of 12-deuterated deoxoartemisinin.....	106	chemistry of.....	502
preparation of 12-titrated deoxoartemisinin from.....	107	<i>N</i> -terminal anthranoyl-phenylalanine	
Artificial neural networks (ANN).....	175	derivatives as.....	501
		CDK serine kinases.....	309
		small-molecule inhibitors of.....	309
		Cellular GSH.....	565
		measurement of.....	565

Central nervous system permeable prodrug (CPPs).....	151	target validation <i>in vivo</i>	203
analeptic activity of.....	150	therapeutic applications of.....	204
IAM chromatography of.....	150	DNA sequences	327
in animals	150	target by mimicking NF- κ B binding sites	327
<i>in vitro</i> metabolic stability studies of.....	150	Docetaxel.....	125
prosolt swim test (PST) of.....	151	structures of.....	125
Cholecystokinins	414	Drugs	635
Chymotrypsin activity	153	development of	635
and malonic acid	153	rationale of	635
circular dichroism (CD) of	154	to treat HIV infection	635
effect of ionic strength upon binding in.....	156	Drug discovery	519,651
effect of negatively charged gold nanoparticles	153	failure/success in modern	519
fluorescence of.....	154	high probability of success in	519
inhibition assays of.....	154	lead likeness in	651
ionic strength studies of.....	155	therapeutic modalities in	520
reversible regulation of.....	153	Drug-like compounds	650
structural studies of.....	155	physicochemical properties of	650
Clinical fate	651	Drug resistant EAC cell line (EAC/Dox)	564
implications of	651	development of	564
Computed property profiles	651	Duocarmycins	13
implications of	651	novel achiral <i>seco</i> -amino-cyclopropylindoline	
Copper	563	(CI) analog of.....	13
in development of drug resistance	563	Ebulin I-anti-human CD105 immunotoxin.....	65
measurement in EAC/3LL cells	566	assay of cell viability of.....	69
measurement in liver cells	566	cytotoxicity of	65
measurement in serum	566	immunodetection of	69
role in murine carcinoma	563	in mouse fibroblasts (L929).....	65
COX-2 inhibitor.....	215	in rat myoblasts (L6E9) cells expressing human	
chemistry of.....	217	CD105.....	65
CYP1A flavonoid ligands	355	SDS-polyacrilamide gel electrophoresis of.....	69
anti-mutagenic properites of	355	western blot analysis of.....	69
computational insight of	355	EGFR family receptor tyrosine kinases	296
dockings of	356	small-molecule inhibitors of.....	296
Cysteine protease inhibitors	81	Enthalpy	182
in clinical development.....	82	Entropy	182
to target caspase-1 (ICE)	82	<i>Escherichia coli</i> metRS	231
to target cathepsin K	83	inhibition by met phosphinate/met phosphonate	233
to target multiple caspases.....	82	Fatty acid-second-generation taxoid conjugates.....	135
to target rhinovirus 3C protease	83	biological evaluation of.....	135
Cysteinyl leukotriene receptor antagonists	414	synthesis of.....	135
opioids as	415	Flexible estrogen receptor modulators	335
somatostatin as	415	antagonistic effects of	335
Delta lactoferrin	59	apoptotic potential of	341
nuclear localization of	59	binding studies of	340
DNA arrays	64	biochemistry of	338
evaluation of gene expression by	64	chemistry of	336
DNA/RNA aptamers	199	cytotoxicity profile of	340
antidote-mediated control of	206	in human MCF-7 breast cancer cells	355
application in therapy	204	rationale of	336
as modulators of protein function	199	role of computational modeling	341
inhibiting protein function of living cells by	202	structure-activity relationships of	335
intracellular expressed	202	synthesis of	335
target validation by	201		

Flt3.....	299	Hepatic mitochondrial carnitine palmitoyltransferases	445
Free energy	182	comparison of (+)-/(-)-hemipalmitoylcarnitinium as	
		inhibitors of	445
		in diabetic rats	445
3- <i>O</i> -(β -D-galacopyranosyl)-6-fluoropyridoxol (GFPOL).....	255	Hepatitis C NS3 protease.....	76
characteristics of	257	Hepatocellular carcinoma (HCC) patients	185
synthesis of	256	Elisa results of	187
β -Galactosidase activity	255	immunohistochemistry results of	186
detection of	255	monoclonal antibodies in	185
using ^{19}F NMR of	255	Herpes simplex virus HSV1716-mediated oncolysis	423
using fluorinated vitamin B ₆ conjugate.....	255	replication of	424
Gene sequence	231	targeted radiotherapy for	423
cloning of	231	transduction of	424
Geranylgeranyl diphosphate (GGdP).....	239	with gene transfer	423
substituted (phosphonoacetamido)oxy		HIV infection	635
analogues of	239	alodine for	637
Geranylgeranyl-diphosphate (GGdP) analogue	239	amdoxovir for	637
as antiproliferative agents.....	239	capravirine for	638
as GGdP-transferase (GGTase) inhibitors	239	elvucitabine for	637
chemistry of.....	240	etravirine for	638
cytotoxicity assay of	244	non-nucleoside reverse transcriptase	
GGTase I/Tase activity assay of	244	inhibitors for	638
Glioma	423	nucleoside/nucleotide reverse transcriptase	
assessment <i>in vitro</i>	423	inhibitors of	636
novel therapeutic strategy for	423	protease inhibitors for	639
Glucosidase-inhibitor complexes	445	tipranavir for	639
free energy perturbation calculations on	455	TMC-114 for	640
Glutathione peroxidase	565	HIV-1 integrase inhibitors.....	263
measurement of	565	computational methods for	265
Glutathione <i>S</i> -transferase Pi isozyme	191	database screening for.....	265
effect of haloenol lactone derivative.....	191	discovery of.....	263
enzyme assays of	197	dock 4.01 docking for	266
expression of mutant (C47A)	197	Dscore scoring function.....	267
expression of wild type.....	196	flexX docking.....	267
inactivation of	191	glide docking for	267
kinetics enzyme inhibition of	197	pharmacophore model development for.....	268
mechanistic studies of.....	191	pharmacophore model for.....	265
modification of.....	197	preparation of 3D sub-databases for.....	265
use of LC-MS/MS.....	197	structure-based drug design of.....	263
Glycoproteins	417	target-based drug design protocol for.....	268
5'-GMP	547	using novel combination of ligand	263
competitive reactions of	547	virtual screening of.....	265,269
role for platinum (II) complexes	547	HIV-1 protease inhibitors	174
GPCR	405	selection of	174
agonists of	405	Human leukemic K562 cells	328
antagonists of	405	effects of extracts of Bangladeshi	
GST peptides.....	197	medicinal plants	328
sequencing of	197	Human recombinant 5-lipoxygenase.....	290
HCO ³⁻ secretion	396	expression of	290
in mucosal protection	399	purification of	290
intracellular mediators in	397	Human tumor cell lines	328
participation of EP4 receptors in	396	effects of extracts of Bangladeshi medicinal	
		plants on	328
		Hyperforin analogues.....	287
		evaluation of.....	287
		inhibition of 5-lipoxygenase by.....	284

Hyperlipidemia	180	assay of	462
ICG-001	467	effect of statin	461
as novel small molecule regulator of		high glucose-induced	461
TCF/ β -catenin transcription	467	MDS-alkanoyltaxoids	133
Immunotoxin 44G4-ebulin I	69	biological evaluation of	134
preparation of	69	synthesis of	133
Inducible nitric oxide synthase	643	MeRS tryptic fragment	231
effect of IL-6	644	production of	231
effect of LPS treatment on expression of	643	purification of	231
in rat model of endotoxemia	643	Metabotropic receptors	418
site-/cell-type-specific induction of	643	Meta-iodobenzylguanidine (MIBG)	611
90K /Mac-2 binding protein (mac-2BP)	185	for combined gene/targeted radiotherapy	611
Elisa results of	187	in bladder carcinoma	611
immunohistochemical studies of	185	radiohalo analogues of	611
in hepatocellular carcinoma patients	185	Metalloprotease inhibitors	92
serological detection of	185	in clinical development	92
KIT family receptor tyrosine kinases	299	to target angiotensin-converting enzyme (ACE)	93
Lectoferrin	57	to target matrix metalloprotease inhibitors	94
and tumor markers	57	to target neutral endopeptidase	94
cell binding of	59	to target tumor necrosis factor-alpha	
confocal microscopy of living cells to	63	converting enzyme	98
cytoplasmic localization of exogenously applied	59	Methionyl-tRNA synthetase	227
dimensional visualization of cells exposed to	59	analysis of kinetic data of	232
dimensional visualization of cells		assay for	232
transfected with	60	bioisosteric effects on	227
entry into cells	59	from <i>Escherichia coli</i>	227
expression in transformed/nontransformed cells	58	interaction of substrates/inhibitors	227
full length/delta display of	57	molecular modeling of	233
immunofluorescence confocal microscopy for	64	Michaelis Menten kinetics	23
role in expression of other genes	57	bayesian studies of	23
role in gene expression	60	for enzyme studies	23
RT-PCR of	62	Mixed monolayer protected clusters (MMPCs)	153
visualization to cells	59	MMP inhibitors	95
Lewis lung carcinoma (3LL/CTx) cell line	565	hydroxamates type	95
<i>in vivo</i>	565	non-hydroxamates type	96
Ligand protein contacts	342	Molecular descriptors	173
Lipodystrophy syndrome	180	calculation of	174
5-Lipoxygenase product formation	290	genetic algorithms (GA) of	175
determination of	290	hydrophobicity of	179
in cell-free systems	291	properties of	179
in intact cells	290	selection of	173
L-methionine	547	shape of	179
competitive reactions of	547	use in HIV-1 protease peptidomimetic	
role for platinum (II) complexes	547	inhibitors activity	173
Lung diseases	49	with artificial intelligence	173
apoptosis signaling pathways in	49	Multidrug resistant (MDR) <i>Staphylococcus aureus</i>	619
in acute lung injury	49	antibacterial activity of	621
in bronchial asthma	52	antitumour antibiotics against	619
MAP kinase activity	461	synthesis of	620
angiotensin II-induced	461	<i>N</i> -(1-benzylpiperidin-4-yl)-4-[¹²³ I]iodobenzamide	31
		biodistribution studies of	37
		in rat brain	31
		<i>in vitro</i> binding assay of	37
		<i>in vivo</i>	31
		influence of trishomocubanes	31

lipophilicity measurements of.....	36	quantitative structure-activity relationship	
radiolabeling of.....	37	analysis of.....	109
sigma receptor binding of.....	31	visualization of.....	113
sigma-1 binding assay of.....	37	P2Y ₁₂	417
sigma-2 binding assay of.....	37	Paclitaxel.....	125
Nanoparticle synthesis (AuDA).....	154	structures of.....	125
Nonreceptor tyrosine kinases.....	296	Papain.....	361
Novel achiral and amino-containing <i>seco</i> -		derived from etacnic acid.....	361
cyclopropylindoline analog.....	13	enzyme assays of.....	365
biological studies of.....	13	non-peptidic inhibitors of.....	361
cytotoxicity studies of.....	17	Parastites.....	168
design of.....	13	Parathyroid hormone.....	418
DNA alkylation of.....	15	Peptide core.....	487
in human chronic myeloid leukemia cells.....	17	Peptide receptors.....	411
synthesis of.....	13	angiotensin II receptor antagonists as.....	411
thermal cleavage studies of.....	17	endothelin as.....	411
Novel gene reporter molecule.....	255	P-glycoprotein (PGP).....	127
evaluation of.....	255	MDR caused by overexpression of.....	127
synthesis of.....	255	Phosphoprotein PhoE.....	537
Novel MAB-second generation taxoid conjugates.....	130	biological activity of.....	537,540
Novel non-nucleoside HIV-1 reverse transcriptase		incorporation into target membranes.....	540
inhibitors.....	277	interaction of.....	537
antimycobacterial screening of.....	284	physicochemical characterization of.....	537
biological investigation of.....	278	secondary structure of.....	539
broad-spectrum anti-microbial properties of.....	277	stimulation of human mononuclear cells	
chemistry of.....	277	(MNC) by.....	545
design of.....	277	with outer membrane lipids.....	537
experimental protocols for.....	279	Phosphoprotein-interaction domain.....	311
HIV-IRT assay of.....	284	containing cellular protein therapeutic targets.....	311
<i>in vitro</i> antibacterial activity of.....	284	inhibitors of.....	311
<i>in vivo</i> antibacterial activity of.....	284	PI-3K-Akt/PKB-mTOR pathway.....	309
synthesis of.....	277	therapeutic targets of.....	309
Nuclear factors.....	327	<i>Plasmodium falciparum</i>	159
medicinal plant extracts inhibiting molecular		drug-resistant species of.....	159
interactions by.....	327	effect of domain structured <i>N</i> ¹ , <i>N</i> ² -derivatized	
[Tyr3] Octreotate derivatives.....	487	hydrazines.....	159
in DMSO.....	487	growth inhibition of.....	159
NMR spectroscopy of.....	489	Propafenone-type modulators.....	431
NOE constraints of.....	489	chemistry of.....	435
3D solution structure of.....	487	CoMFA/CoMSIA studies of.....	436
structure differentiation of.....	487	hologram based QSAR analysis of.....	431
Oligonucleotides.....	200	HQSAR studies of.....	437
as inhibitors of protein function.....	200	interaction field based analysis of.....	431
Oligonucleotide aptamers.....	204	multidrug resistance of.....	431
counteracting VEGF pathophysiology by.....	204	pharmacological activity of.....	438
Opioid receptor modulators.....	601	virtual screening of.....	441
chemistry of.....	601	Prostaglandins.....	396
8-(heteroaryl)phenalkyl-1-phenyl-1,3,8		stimulation of HCO ³⁻ secretion by.....	396
tiazaspiro[4.5]decan-4-ones as.....	601	Prostaglandin E receptor subtypes.....	395
P2X ₂ channel.....	109	in HCO ³⁻ response induced by mucosal	
cation permeability of.....	109	acidification.....	398
3D-model of.....	113	role in gastroduodenal HCO ³⁻ secretion.....	395
perspectives in drug design of.....	115	studies using mice lacking EP1/EP3 receptors.....	399
		Prostanoid receptors.....	408

Protease inhibitors	71	nucleotide-composition based fingerprint of	39
to target factor Xa	75	visualization analysis of	39
Protein-DNA interactions	329	Second-generation taxane anticancer agents	126
plant extracts and inhibition of	329	development of	126
Protein kinase	296	Secretin-like receptors	418
inhibitors of	296	calcitonin as	418
therapeutic targets of	296	glucagon as	418
Protein phosphatase	310	Serine protease inhibitors	72
inhibitors of	310	in clinical development	73
therapeutic targets of	310	to target chymase	80
Protein phosphorylation	293	to target dipeptidyl peptidase IV	78
and signal transduction modulation	293	to target elastase	77
Protein synthesis	69	to target factor Xa	75
in cell-free extracts	69	to target multiple serine proteases	79
Protein therapy	521	to target thrombin	72
Pyrrol-1-yl-acetic acid derivatives	321	to target urokinase-type plasminogen activator	78
analysis of	324	Silicon isosteres	215
modeling of aldose reductase inhibitory		effects of	215
activity of	321	in COX-2 inhibitors	215
role of multivariate statistics	321	preliminary <i>in silico</i> evaluation	215
validation of model for	325	Sinfit package	23
3-(1 <i>H</i> -pyrrol-2-yl)-2-oxazolidinones	117	modeling of stimulated data using	23
as novel monoamine oxidase type A inhibitors	117	Small molecule drug discovery	521
biochemical assay of	123	high probability of	524
chemistry of	118	in age of biochemical assay	521
synthesis of	121	Small-molecule drug discovery	293,314
		chemistry perspectives	293,314
Quinaldine derivatives	591	Small molecule therapy	521
antifungal susceptibility testing of	596	Src family non receptor tyrosine kinases	301
biological activity of	591	Statin	461
herbicidal activities of	593,596	inhibition of NAD(P)H oxidase activity by	461
preparation of	591	Steady-state processes	21
synthesis of	594	novel experimental design for	21
Ras-Raf-MEK pathway	309	Structured <i>N</i> ¹ , <i>N</i> ² -derivatized hydrazines	159
therapeutic targets of	309	dentcity effects by	159,163
Receptor/nonreceptor serine/threonine	307	electronic effect of	164
dual specificity kinases of	307	iron affinity of	164
Resveratrol	629	mechanism of action of	167
effect on DNA strand breaks after UVA		redox switches of	159
irradiation	630	reductant driven redox-cycling by	159
in HaCaT human keratinocytes	629	substitution effects of	164
potentiates UVA-induced cell death	630	Superoxide dismutase (SOD)	566
Rhodopsin-like GPCR families	406	measurement of	566
α Rhodopsin receptors	406	Synthesis	105,154
β Rhodopsin receptors	412	circular dichroism (CD) of	154
neurokinin NK1 as	413	fluorescence of	154
oxytocin as	413	inhibition assays of	154
δ Rhodopsin	417	of 12-deuterated deoxoartemisinins	105
γ Rhodopsin	414	of 2-(10-mercapto-decyl)-malonic acid	154
		of tritiated deoxoartemisinins	105
SARS-coronavirus (SARS-CoV)	39	Systematic bayesian approach	21
fingerprint of	40	applicability to study of continuous culture/	
		drug/receptor binding kinetics	27
		for cell transport kinetics	21
		for continuous culture	21

for drug transport	21	as central nervous system agents	141
for enzymes	21	<i>in vivo</i> stability studies of	146
for receptor binding	21	membrane affinity of	146
in cell transport kinetics	26	prodrugs of	141
rules for	25	prosolet swim test of	147
utility functions of	22	pyridinium-substituted analog of	141
		solid phase synthesis of	149
		synthesis of	143
Talampanel related 1-benzodiazepines	481	Tubulin-bound paclitaxel conformation	129
synthesis of	481	structure-based drug design of	129
Taxane anticancer agents	125	Tumor markers	57
biological evaluation of	134	Type I cleavable complex inhibitors	386
recent advances in	125	Type II catalytic inhibitors	388
TGF β R serine kinase	308		
small-molecule inhibitors of	308	Unifiram (DM232)	473
Threonine protease inhibitors	80	as cognition-enhancing agent	473
in clinical development	80	chemistry of	476
Thrombin	72	enantiomeric excess to	474
Thyrotropin-releasing hormone	414	enantiomers of	473
Topoisomerase enzymes	383	enantioselective synthesis of	473
as targets for cancer chemotherapy	383	pharmacology of	474
DNA topology of	383	preliminary pharmacological evaluation of	473
Topoisomerase inhibitors	386	use of capillary electrophoresis	480
adverse secondary effects of	389	UVA-induced DNA damage	629
cytotoxic mechanism of	389	effect of resveratrol	629
development of drug resistance of	390	in HaCaT human keratinocytes	629
drug development strategies of	391		
function of	386	VEGFR	299
pharmacology of	389	Virtual HTS (vHTS)	182
structure of	386		
TRH-like tripeptide pGlu-Glu-Pro-NH ₂	141		
analeptic effects of	146		